Royal Pharmaceutical Society of Great Britain, London
Monday 20-Tuesday 21 October 2008
Monday 20 October Keynote Presentations
13:00 – 13:10 Introduction and Welcome Vinod P. Shah, FIP, BPS, USA
13:10 – 13:50 Current views of European Pharmacopeia on the Drug Release of Special Dosage Forms Susanne Keitel, EDQM, Germany
13:50 – 14:30 Overview of USP Dosage Form Taxonomy Todd Cecil, USP, USA
14:30 – 15:10 Overview of Current FIP SDF White Paper Jennifer Dressman, University of Frankfurt, Germany
15:10 – 15:30 Coffee Break Session 1: Specialized Oral Dosage Forms
Moderators: Jennifer Dressman, University of Frankfurt, Germany and Cynthia Brown, Eli Lilly & Compnay, USA
15:30 – 16:10 Orally Disintegrating Tablets – Disintegration vs Dissolution Lucinda Buhse, FDA, USA
16:10 – 16:50 Buccal Dosage Forms Munir Hussain, Bristol Meyer Squibb, USA
16:50 – 17:30 Chewable Oral Drug ProductsJ ohannes Kraemer, PHAST, Germany
17:30 – 18:00 Panel Discussion Tuesday 21 October
Session 2: Non-Oral Dosage Forms
Moderators: Johannes Kraemer, PHAST, Germany and Mary Stickelmeyer, Eli Lilly & Company, USA
08:00 – 08:10 Welcome – Session Overview
08:10 – 08:50 Topical Clarence Ueda, University of Nebraska, USA
08:50 - 09:30 Opthalmics Larry Stevens, Alcon Research, USA
09:30 -10:00 Break
10:00 – 10:40 Drug-eluting Stents - Industry Perspective Lori Allgeuier, Cordis, USA
10:40 – 11:20 Drug-eluting Stents - Regulatory Perspective Angelica Durantes, FDA , USA
11:20 – 12:00 Panel Discussion
12:00 – 13:00 Lunch Session 3: Special Dosage Forms
Moderators: Mike Morris, Irish Medicines Board, Ireland and Todd Cecil, United States Pharmacopeia, USA
13:00 – 13:40 Microspheres Siddhesh Patil, Amylin, USA
13:40 – 14:20 Nanoparticles Roy De Maesshlack, Johnson & Johnson, Belgium
14:20 – 15:00 Liposomes Dr Hiroshi Kikuchi, Eisai Co.,Japan
15:00 – 15:30 Break
15:30 – 16:10 Is It Time for In Vitro Release Testing of Inhalation Dosage Forms? Neal Davies, University of Washington, USA
16:10 – 16:40 In vitro release of suppositories TBC
16:40 – 17:20 Panel Discussion
17:20 – 17:30 Conclusions and next steps
|
|
|
Invited Speakers:
|
|
Horst-Dieter Friedel, Bayer HealthCare AG, GermanyCynthia K. Brown, Eli Lilly & Company, USAVinod P. Shah, FIP Scientific Secretary, USALucinda Buhse, Food and Drug Administration (FDA), USASusanne Kietel, European Directorate for the Quality of Medicines and Healthcare, GermanyMary Stickelmeyer, Eli Lilly & Company, USAJohannes Kraemer, PHAST, GermanyTodd Cecil, United States Pharmacopeia, USAMike Morris, Irish Medicines Board, Ireland
|
|